

Xue-Kun Liu, Xiao-Yu Geng, Meng Zhang, Bai-Jun Ye, Zhan Shi and Yan-Qiu Wang*

Crystal structure of ethyl 2-amino-4-(3,4-dimethylphenyl)-5-oxo-4*H*,5*H*-pyrano[3,2-*c*]chromene-3-carboxylate, C₂₃H₂₁NO₅




Table 1: Data collection and handling.

Crystal:	Yellow block
Size:	0.26 × 0.21 × 0.17 mm
Wavelength:	Mo K α radiation (0.71073 Å)
μ :	0.10 mm ⁻¹
Diffractometer, scan mode:	Bruker APEX-II CCD, φ and ω
$\theta_{\max}$, completeness:	25.0°, >99%
$N(hkl)_{\text{measured}}$, $N(hkl)_{\text{unique}}$, R_{int} :	9255, 3383, 0.178
Criterion for I_{obs} , $N(hkl)_{\text{gt}}$:	$I_{\text{obs}} > 2 \sigma(I_{\text{obs}})$, 2167
$N(\text{param})_{\text{refined}}$:	262
Programs:	Olex2 [6], SHELX [7], Bruker [8]

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	<i>x</i>	<i>y</i>	<i>z</i>	$U_{\text{iso}}^*/U_{\text{eq}}$
N1	0.21672(15)	0.9825(3)	−0.02116(14)	0.0521(7)
H1A	0.231061	1.081108	−0.010702	0.063*
H1B	0.208941	0.948787	−0.076265	0.063*
O1	0.07671(11)	0.4036(2)	0.18123(11)	0.0434(5)
O2	0.11407(13)	0.5466(3)	0.30259(11)	0.0505(6)
O3	0.18553(12)	0.7305(2)	0.01495(11)	0.0444(5)
O4	0.24960(13)	1.0899(2)	0.25719(12)	0.0505(6)
O5	0.24809(13)	1.1921(3)	0.11570(13)	0.0536(6)
C1	0.11396(15)	0.4835(3)	0.03219(16)	0.0370(6)
C2	0.11103(17)	0.4484(4)	−0.06107(17)	0.0436(7)
H2	0.135940	0.518351	−0.101043	0.052*
C3	0.07167(18)	0.3118(4)	−0.09335(19)	0.0496(8)
H3	0.070219	0.289224	−0.155311	0.060*
C4	0.0339(2)	0.2066(4)	−0.0351(2)	0.0533(8)
H4	0.007487	0.113705	−0.057932	0.064*
C5	0.03537(18)	0.2393(4)	0.0567(2)	0.0481(7)
H5	0.009069	0.170390	0.096152	0.058*
C6	0.07615(16)	0.3749(3)	0.08905(17)	0.0388(7)
C7	0.11722(16)	0.5338(3)	0.22093(16)	0.0376(6)
C8	0.15953(15)	0.6455(3)	0.16413(15)	0.0336(6)
C9	0.15324(15)	0.6214(3)	0.07370(16)	0.0355(6)
C10	0.20659(16)	0.8823(3)	0.04783(17)	0.0373(6)
C11	0.21622(15)	0.9152(3)	0.13827(16)	0.0364(6)
C12	0.20980(16)	0.7804(3)	0.20706(16)	0.0363(7)
H12	0.179553	0.821434	0.258510	0.044*
C13	0.23834(16)	1.0766(4)	0.16574(18)	0.0407(7)
C14	0.2795(2)	1.2425(4)	0.2942(2)	0.0591(9)
H14A	0.231768	1.308251	0.309674	0.071*
H14B	0.310211	1.299891	0.249115	0.071*
C15	0.3354(2)	1.2141(5)	0.3760(3)	0.0803(12)

<https://doi.org/10.1515/ncrs-2018-0023>

Received March 13, 2018; accepted June 12, 2018; available online June 27, 2018

Abstract

C₂₃H₂₁NO₅, monoclinic, $P2_1/c$ (no. 14), $a = 15.829(11)$ Å, $b = 8.294(6)$ Å, $c = 14.718(10)$ Å, $\beta = 93.339(12)^\circ$, $V = 1929(2)$ Å³, $Z = 4$, $R_{\text{gt}}(F) = 0.073$, $wR_{\text{ref}}(F^2) = 0.206$, $T = 296(2)$ K.

CCDC no.: 1848831

The crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.

*Corresponding author: Yan-Qiu Wang, Tonghua Health School, Tonghua 134002, China, e-mail: yanqiu_wang666@yeah.net

Xue-Kun Liu and Xiao-Yu Geng: Tonghua Normal University, Tonghua 134002, China

Meng Zhang: Tonghua Health School, Tonghua 134002, China

Bai-Jun Ye: State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300071, China

Zhan Shi: State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, College of Chemistry, Jilin University, Changchun 130000, China

Table 2 (continued)

Atom	<i>x</i>	<i>y</i>	<i>z</i>	<i>U</i> _{iso} [*] / <i>U</i> _{eq}
H15A	0.355113	1.315539	0.400385	0.120*
H15B	0.304585	1.158291	0.420668	0.120*
H15C	0.382833	1.149952	0.360261	0.120*
C16	0.29669(15)	0.7195(3)	0.24325(16)	0.0375(7)
C17	0.32843(17)	0.7607(4)	0.32888(18)	0.0478(8)
H17	0.295376	0.823052	0.365520	0.057*
C18	0.4083(2)	0.7125(4)	0.3627(2)	0.0569(9)
C19	0.4383(3)	0.7657(7)	0.4576(2)	0.1021(16)
H19A	0.395364	0.830145	0.483307	0.153*
H19B	0.449517	0.672484	0.495126	0.153*
H19C	0.489197	0.828022	0.454628	0.153*
C20	0.45718(18)	0.6175(5)	0.3087(2)	0.0600(9)
C21	0.5442(2)	0.5594(6)	0.3410(3)	0.0977(15)
H21A	0.557255	0.597294	0.401862	0.147*
H21B	0.545301	0.443716	0.340365	0.147*
H21C	0.585247	0.600337	0.301444	0.147*
C22	0.42543(19)	0.5772(4)	0.2229(2)	0.0614(9)
H22	0.458155	0.514712	0.185938	0.074*
C23	0.34607(17)	0.6269(4)	0.18995(19)	0.0498(8)
H23	0.326074	0.597578	0.131610	0.060*

Source of material

The title compound was prepared by a reported method. A mixture of 4-hydroxycoumarin (10 mmol), 3,4-dimethylbenzaldehyde (10 mmol), Ethyl cyanoacetate (10 mmol) and 4-(dimethylamino)pyridine (DMAP) (1 mmol) in ethanol (100 mL) was refluxed for 2–3 h and then cooled to room temperature. After filtering the precipitates, they were sequentially washed with ice-cooled water and ethanol and then dried under a vacuum.

Experimental details

H atoms were positioned geometrically and refined using a riding model, with C–H = 0.93 or 0.96 Å and N–H = 0.86 Å with *U*_{iso}(H) = 1.2 times *U*_{eq}(C) and 1.2 times *U*_{eq}(N).

Comment

Natural products have a profound impact on both chemical biology and drug discovery, and the great structural diversity of natural products with various interesting biological characteristics has always provided medicinal chemists an important source of inspiration in their search for new molecular

entities with pharmacological activity [1, 2]. Among them, coumarin derivatives are one important group of compounds covering a wide range of biological properties, including anti-oxidant, anti-inflammatory and anti-microbial as well as anti-cancer activities [3, 4].

In the crystal structures of the title compound (Figure), the pyran moiety is slightly folded, whereas the adjacent coumarin moiety is basically planar. But the best planes of these units are essentially parallel to each other. However, the phenyl plane makes a torsion angle to the pyran moiety. The bond distances and the bond angles present in the title compound are comparable with those known related compounds. The structural features of the title compound are very similar to the previously reported compounds C₂₂H₁₉NO₆, C₂₁H₁₆N₂O₇ and C₂₇H₂₁NO₆ [5]. Compared with these three known coumarin derivatives, the most differences laid on their different functional groups, which are –OCH₃, –NO₂ and –OC₆H₅, respectively. While the title compound has two –CH₃ functional groups bridging two carbon atoms from benzene ring.

References

- Wang, Y.; Ba, Y.: Studies on the chemical constituents of Radix astragali and their inhibitory effect on HepG₂ proliferation. *Biomed. Res.-India* **26** (2015) 393–398.
- Kahsai, A. W.; Cui, J.; Kaniskan, H. Ü.; Garner, P. P.; Fenteany, G.: Analogs of tetrahydroisoquinoline natural products that inhibit cell migration and target galectin-3 outside of its carbohydrate-binding site. *J. Biol. Chem.* **283** (2008) 24534–24545.
- Wang, X. K.; Li, P. W.; Yan, B.; Wang, B.-J.: 1,4-Dihydropyridine derivatives: synthesis and anti-hepatoma cancer activity. *Lat. Am. J. Pharm.* **35** (2016) 1692–1695.
- Gündüz, M. G.; Celebi, S.; Kaygisiz, B.; Safak, C.: 7-Substituted hexahydroquinoline derivatives and their calcium channel modulator effects. *Lat. Am. J. Pharm.* **28** (2009) 922–926.
- Chen, H. L., Yang, G. L., Liao, X. Y., Bao, Z. Y.; Zhang, X. R.: Novel coumarins from traditional chinese medicine: synthesis and anti-lung cancer activity. *Lat. Am. J. Pharm.* **37** (2018) 384–387.
- Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H.: OLEX2: a complete structure solution, refinement and analysis program. *J. Appl. Crystallogr.* **42** (2009) 339–341.
- Sheldrick, G. M.: Crystal structure refinement with SHELXL. *Acta Crystallogr.* **C71** (2015) 3–8.
- Bruker. APEX2. Bruker AXS Inc., Madison, WI, USA (2008).